miR-146a overexpression in PBMCs was also demonstrated in MS patients, and again, it was associated with increased Th1/Th17 cytokine overexpression (e.g. IL-17, IFN-γ, TNF-α) (67). Here, IL17A is linked to myeloid sarcoma.